Yüklüyor......
Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report
Following the ATTRACTION-2 study, nivolumab was approved for advanced gastric cancer in Japan. However, pseudoprogression and hyperprogressive disease have been reported in patients treated with immune checkpoint inhibitors. We report a patient with gastric cancer who received nivolumab after radiot...
Kaydedildi:
| Yayımlandı: | Case Rep Oncol |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
S. Karger AG
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5903152/ https://ncbi.nlm.nih.gov/pubmed/29681813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000487477 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|